Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Echinobase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Echinobase
ECB-ART-51972
Front Med (Lausanne) 2023 Jan 01;10:1031998. doi: 10.3389/fmed.2023.1031998.
Show Gene links Show Anatomy links

Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease.

Lenti MV , Scribano ML , Biancone L , Ciccocioppo R , Pugliese D , Pastorelli L , Fiorino G , Savarino E , Caprioli FA , Ardizzone S , Fantini MC , Tontini GE , Orlando A , Sampietro GM , Sturniolo GC , Monteleone G , Vecchi M , Kohn A , Daperno M , D'Incà R , Corazza GR , Di Sabatino A .


???displayArticle.abstract???
Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a complex, immune-mediated, disorder which leads to several gastrointestinal and systemic manifestations determining a poor quality of life, disability, and other negative health outcomes. Our knowledge of this condition has greatly improved over the last few decades, and a comprehensive management should take into account both biological (i.e., disease-related, patient-related) and non-biological (i.e., socioeconomic, cultural, environmental, behavioral) factors which contribute to the disease phenotype. From this point of view, the so called 4P medicine framework, including personalization, prediction, prevention, and participation could be useful for tailoring ad hoc interventions in IBD patients. In this review, we discuss the cutting-edge issues regarding personalization in special settings (i.e., pregnancy, oncology, infectious diseases), patient participation (i.e., how to communicate, disability, tackling stigma and resilience, quality of care), disease prediction (i.e., faecal markers, response to treatments), and prevention (i.e., dysplasia through endoscopy, infections through vaccinations, and post-surgical recurrence). Finally, we provide an outlook discussing the unmet needs for implementing this conceptual framework in clinical practice.

???displayArticle.pubmedLink??? 37113615
???displayArticle.link??? Front Med (Lausanne)



References [+] :
Aberra, Risk for active tuberculosis in inflammatory bowel disease patients. 2007, Pubmed